Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment

Sclerostin, a protein produced by osteocytes, inhibits bone formation. Administration of sclerostin antibody results in increased bone formation in multiple animal models. Romosozumab, a humanized sclerostin antibody, has a dual effect on bone, transiently increasing serum biochemical markers of bon...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Bone Miner Res
Auteurs principaux: Chavassieux, Pascale, Chapurlat, Roland, Portero‐Muzy, Nathalie, Roux, Jean‐Paul, Garcia, Pedro, Brown, Jacques P, Libanati, Cesar, Boyce, Rogely W, Wang, Andrea, Grauer, Andreas
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027577/
https://ncbi.nlm.nih.gov/pubmed/31233639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.3735
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires